Evernorth, the health services division of Cigna, is debuting a pharmacy benefit management program geared to make Wegovy and Zepbound more available to patients by capping the amount they spend ...

Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...

Cigna's Evernorth is signaling that it will expand its GLP-1 medication offerings through the creation of Evernorth EnReachRx, a new patient support model for pharmacies that want to provide enhanced ...

Cigna, which includes Evernorth Health Services and one of the nation’s largest pharmacy benefit management companies, said first quarter net income was $1.3 billion, or $4.85 per share ...

Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.